| Name | Title | Contact Details |
|---|
A-MAX Auto Insurance is a Texas-based insurance provider founded in 2002, with its headquarters in Dallas. The company specializes in affordable insurance solutions and has rapidly expanded to operate over 200 offices across Texas. In 2022, A-MAX entered the California market by acquiring Sameday Insurance, adding 10 locations in Southern California. A-MAX offers a wide range of insurance products, including auto insurance for cars, motorcycles, boats, RVs, and commercial vehicles. They also provide property insurance for homeowners, renters, and mobile homes, along with specialized services such as SR-22 certificates, Mexico tourist insurance, surety bonds, and notary services. Additionally, A-MAX has commercial solutions, including general liability and commercial auto insurance. The company operates two subsidiaries in Texas: ALPA Auto Insurance and Preferred Coverage Insurance Agency, catering to both non-standard and commercial/personal insurance needs. A-MAX focuses on delivering flexible, customer-centric service to individual consumers and businesses.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Nexxess International is a National Private Trust Management Company, located near Dallas, TX. Today, Nexxess has more than 200 consulting partners and we manage wealth and trusts for clients. As a leader in complex trust structuring, Nexxess can help both clients, large or small. We have staff of many different skill sets, including Financial Planners, Enrolled Agents, CPAs, Attorneys and more.